Browse 126 market data tables and 38 figures spread through 200 Pages and in-depth TOC on “Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Immunology, Hematology, Critical Care) & by End-user (Hospitals, Clinical Research Laboratories) - Global Forecast to 2019”.
http://www.marketsandmarkets.com/Market-Reports/plasma-fractionation-market-93798284.html
Early buyers will receive 10% customization on reports.

This report studies the plasma fractionation market over the forecast period of 2014-2019.

The plasma fractionation market saw healthy growth during the last decade, primarily attributed to the rising aging population, increasing number of hemophilic patients, rising off-label use of albumin and immunoglobulins in various chronic diseases, increased diagnosis rate, and the increasing use of prophylactic treatment for bleeding disorders and disease of immune systems. However, the high cost and serious adverse effects of plasma products, and the emergence of recombinant products used as alternatives to plasma-derived products are hampering the growth of this market to a certain extent.

In this report, the market is segmented by products, applications, end users, and region. Based on type of product, this market is mainly segmented into albumin, immunoglobulins, coagulation factor concentrates, and others. The immunoglobulin segment is further subsegmented into intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and others. The coagulation factor concentrates segment is divided into factor VIII, factor IX, factor XIII, prothrombin coagulation concentrates, Von Willebrand factor, and fibrinogen concentrates. The various application areas of plasma fractionation products analyzed in the report include neurology, hematology, immunology, and critical care. Likewise, the major end users of this market are hospitals and clinics, clinical research laboratories, and academic institutes.

IVIg accounts for the major share of the market. The increasing use of IVIg in clinical areas such as neurology, hematology, immunology, rheumatology, and dermatology, and its excellent efficacy records are the key factors responsible for the growth of this market segment. In addition, the use of IVIg in a wide range of conditions, such as adult respiratory distress syndrome, fibrosis, connective tissue disease, encephalitis, heart failure, and Alzheimer’s disease, is being evaluated. Positive results in such conditions would increase the demand for IVIg globally in the near future.

In 2013, North America was the leading market for plasma fractionation, followed by Europe, and Asia-Pacific. The highly developed healthcare infrastructure, advent of new technologies, growing aging population, and favorable regulatory framework in the North American and European regions has led to the large market shares of these regions. However, the highest growth opportunities for this market are in the Asia-Pacific region.

The major players in the global market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.), Sanquin (Netherland), Laboratoire Français du Fractionnement et des Biotechnologies (France), and Biotest (Germany).